|
|
||||||||
1 Cardiovascular Research Institute and Departments of 2 Pediatrics and 4 Pharmacy, University of California, San Francisco, San Francisco, California 94143-0544; and 3 Research Center, Hôpital Sainte-Justine, Montreal, Quebec, Canada H3T IC5
Nonselective cyclooxygenase (COX)
inhibitors are potent tocolytic agents; however, they also have adverse
fetal effects such as constriction of the fetal ductus arteriosus.
Recently, selective COX-2 inhibitors have been used in the management
of preterm labor in the hope of avoiding fetal complications. However,
both COX-1 and -2 are expressed by cells of the ductus arteriosus. We
used fetal lambs (0.88 gestation) to assess the ability of selective COX-2 inhibitors celecoxib and NS398 to affect the ductus arteriosus. Both selective COX-2 inhibitors decreased PGE2 and
6ketoPGF1
production in vitro; both inhibitors
constricted the isolated ductus in vitro. The nonselective COX-1/COX-2
inhibitor indomethacin produced a further reduction in PG release and
an additional increase in ductus tension in vitro. We used a prodrug of
celecoxib to achieve 1.4 ± 0.6 µg/ml, mean ± standard deviation,
of the active drug in vivo. This concentration of celecoxib produced
both an increase in pressure gradient and resistance across the ductus; celecoxib also decreased fetal plasma concentrations of
PGE2 and 6ketoPGF1
. Indomethacin
(0.7 ± 0.2 µg/ml) produced a significantly greater fall in ductus
blood flow than celecoxib and tended to have a greater effect on ductus
resistence in vivo. We conclude that caution should be used when
recommending COX-2 inhibitors for use in pregnant women, because COX-2
appears to play a significant role in maintaining patency of the fetal
ductus arteriosus.
cyclooxygenase; cyclooxygenase-1; cyclooxygenase-2; prostaglandin E2; prostaglandin I2; indomethacin; celecoxib
This article has been cited by other articles:
![]() |
P. Agren, A. L. Cogolludo, C. G. A. Kessels, F. Perez-Vizcaino, J. G. R. De Mey, C. E. Blanco, and E. Villamor Ontogeny of chicken ductus arteriosus response to oxygen and vasoconstrictors Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R485 - R496. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Zeytin, A. C. Patel, C. J. Rogers, D. Canter, S. D. Hursting, J. Schlom, and J. W. Greiner Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice Cancer Res., May 15, 2004; 64(10): 3668 - 3678. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bouayad, J.-C. Fouron, X. Hou, M. Beauchamp, C. Quiniou, D. Abran, K. Peri, R. I. Clyman, D. R. Varma, and S. Chemtob Developmental regulation of prostaglandin E2 synthase in porcine ductus arteriosus Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R903 - R909. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Granger Maternal and fetal adaptations during pregnancy: lessons in regulatory and integrative physiology Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2002; 283(6): R1289 - R1292. [Full Text] [PDF] |
||||
![]() |
E N Harris Antirheumatic drugs in pregnancy Lupus, October 1, 2002; 11(10): 683 - 689. [PDF] |
||||
![]() |
H. Ehmke Developmental physiology of the cardiovascular system Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2002; 282(2): R331 - R333. [Full Text] [PDF] |
||||
![]() |
D. H. Wright, D. Abran, M. Bhattacharya, X. Hou, S. G. Bernier, A. Bouayad, J.-C. Fouron, A. Vazquez-Tello, M. H. Beauchamp, R. I. Clyman, et al. Prostanoid receptors: ontogeny and implications in vascular physiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1343 - R1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fosslien Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sakai, K. Tanebe, Y. Sasaki, K. Momma, S. Yoneda, and S. Saito Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery Mol. Hum. Reprod., June 1, 2001; 7(6): 595 - 602. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |